Eloxx Pharmaceuticals Announces First Patients Dosed in Phase 2b EXACT Study of Exaluren in Nonsense Mutation Alport Syndrome

Summary

Eloxx Pharmaceuticals announced dosing of the first two patients in the Phase 2b EXACT study of Exaluren for nonsense mutation Alport Syndrome, with topline data from the initial 16-week placebo-controlled portion expected mid-2027 and final readout by end of 2027.